Literature DB >> 31364034

Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications.

Kristofor Yap1, Evan N Cohen1, James M Reuben1, Joseph D Khoury2.   

Abstract

PURPOSE OF REVIEW: Circulating tumor cells represent rare events in the peripheral blood of patients with cancer that can provide insight into tumor biology. CTC enumeration, isolation, and analysis represent liquid biopsy approaches whose role in the management of patients with cancer continues to evolve in the era of precision medicine. This review presents an overview of technologies central to studying CTCs. RECENT
FINDINGS: Technologies for CTC isolation can be divided into two categories: label-dependent and label-independent. Label-dependent techniques utilize biological properties such as cell surface proteins, while label-independent techniques utilize distinctive physical properties such as cell size, density, and plasticity. Advances in microfluidics designs as well as hybrid combinations of label-dependent and label-independent techniques have resulted in unprecedented improvements in CTC isolation, permitting not only the detection and enumeration of these rare events but also providing the means for studying them and exploring them as a new dimension of cancer biomarkers. With advances in tools for isolating and studying CTCs in hand, questions regarding the clinical utility of CTC enumeration in peripheral blood, detection of CTC-associated biomarkers, and analysis of dynamic changes in CTCs during the course of cancer therapy represent exciting new opportunities for cancer research.

Entities:  

Keywords:  Biomarker; Cancer; Circulating tumor cells

Year:  2019        PMID: 31364034     DOI: 10.1007/s11899-019-00531-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  28 in total

Review 1.  CTC enumeration and characterization: moving toward personalized medicine.

Authors:  Angela Toss; Zhaomei Mu; Sandra Fernandez; Massimo Cristofanilli
Journal:  Ann Transl Med       Date:  2014-11

2.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

Review 3.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

4.  Cancer. Circulating tumor cells.

Authors:  Vicki Plaks; Charlotte D Koopman; Zena Werb
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

5.  Going with the flow: from circulating tumor cells to DNA.

Authors:  Francois-Clement Bidard; Britta Weigelt; Jorge S Reis-Filho
Journal:  Sci Transl Med       Date:  2013-10-16       Impact factor: 17.956

6.  Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

Authors:  Volkmar Müller; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Erich Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Klaus Pantel; Tanja Fehm
Journal:  Breast Cancer Res       Date:  2012-08-15       Impact factor: 6.466

Review 7.  Biology, detection, and clinical implications of circulating tumor cells.

Authors:  Simon A Joosse; Tobias M Gorges; Klaus Pantel
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

8.  Absolute quantification of somatic DNA alterations in human cancer.

Authors:  Scott L Carter; Kristian Cibulskis; Elena Helman; Aaron McKenna; Hui Shen; Travis Zack; Peter W Laird; Robert C Onofrio; Wendy Winckler; Barbara A Weir; Rameen Beroukhim; David Pellman; Douglas A Levine; Eric S Lander; Matthew Meyerson; Gad Getz
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 10.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

View more
  1 in total

1.  Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization.

Authors:  Evan N Cohen; Gitanjali Jayachandran; Max R Hardy; Ananya M Venkata Subramanian; Xiangtian Meng; James M Reuben
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.